ecently, much attention has been paid to the relationship between chronic kidney disease and cardiovascular events. [1] [2] [3] [4] [5] [6] [7] [8] Renal function is estimated by serum creatinine concentration or estimation of creatinine clearance by the Cockcroft-Gault and Modification of Diet in Renal Disease (MDRD) equations. 7, 8 However, creatinine concentration is an unreliable estimate of the glomerular filtration rate (GFR), 1,2 because it is influenced by factors such as age, gender, muscle mass, physical activity, and diet. 9 Because of the nonlinear relationship between creatinine concentration and GFR, it is insensitive to small decreases in GFR or mild renal dysfunction. 10 Cystatin C is a cysteine protease inhibitor involved in the catabolism of proteins. It is produced in all nucleated cells at a constant rate and is freely filtered by the glomerulus without secretion or subsequent reabsorption to the blood flow. 11 Because it has been shown that cystatin C is a better endogenous marker of GFR than serum creatinine, 11, 12 the prognostic value of cystatin C in patients with ST-elevation myocardial infarction (MI) was evaluated in the present study.
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Methods
Patients
Between December 2006 and July 2007, 72 consecutive patients underwent percutaneous coronary intervention (PCI) for ST-segment elevation MI <24 h from symptom onset at Chiba Cardiovascular Center. ST-segment elevation MI was diagnosed by (1) typical chest pain lasting >30 min, (2) ST-segment elevation in at least 2 contiguous leads or left bundle-branch block, and (3) typical increase and decrease of serum creatine kinase concentration above twice the upper limit of normal. Exclusion criterion was age 90 years and over (n=1). Thus 71 patients were included in the present study. PCI was performed using standard techniques after written informed consent was given. Before discharge (13.5±3.5 days after admission), coronary angiography and left ventriculography were repeated. This study was approved by the local council on human research.
Laboratory Analysis
Before PCI, blood samples were collected and serum cystatin C measurement was performed by colloidal gold particle-enhanced colorimetric immunoassay (Nescauto GC Background: Cystatin C is reportedly a better endogenous marker of glomerular filtration rate than serum creatinine, so the prognostic value of cystatin C in patients with ST-elevation myocardial infarction (MI) was evaluated in the present study.
Methods and Results:
A total of 71 patients who underwent percutaneous coronary intervention for ST-segment elevation MI <24 h from symptom onset were included. According to cystatin C level, patients were classified into 2 groups: (1) higher cystatin C group (n=33) and (2) lower cystatin C group (n=38). There was a trend toward more in-hospital deaths in patients with the higher cystatin C level compared with the lower cystatin C level group (15.2% vs 2.6%, P=0.06). Mean duration of clinical follow-up was 5.6±2.8 months. There was no significant difference in death, reinfarction, disabling stroke or target lesion revascularization between the 2 groups. However, a higher incidence of rehospitalization for congestive heart failure was observed in patients with the higher cystatin C level than in those with the lower cystatin C level (15.2% vs 0%, P=0.01).
Conclusions: Cystatin C may be associated with more cardiovascular events, mainly rehospitalization for congestive heart failure, after percutaneous coronary intervention in patients with ST-elevation MI. Cystatin C, Alfresa Pharma, Osaka, Japan) with a Hitachi 7600-110 automatic analyzer. Serum creatinine concentration was determined by enzymatic assay (Aquaauto Kainos CRE-II, Kainos, Tokyo, Japan). The upper reference level was 1.04 mg/dl. Estimated GFR (eGFR) was calculated according to the MDRD equation modified for Japanese patients. 13
Follow-up
All patients received aspirin 100 mg daily indefinitely. Ticlopidine 100 mg twice daily was given for at least 1 month to patients undergoing stenting. Baseline demographic and clinical data along with in-hospital outcomes were obtained by review of the medical records and procedural reports. Clinical follow-up data were obtained from outpatient record reviews or telephone interviews. General practitioners, referring cardiologists, and patients were contacted as necessary for additional information. Reinfarction was defined by the presence of recurrent ischemic symptoms or electrocardiographic changes accompanied by a creatine kinase concentration that was more than twice the upper limit of the normal range or more than 50% higher than the previous value obtained during hospitalization. Disabling stroke was defined as an acute neurologic deficit that lasted more than 24 h and affected the ability to perform daily activities or resulted in death. Heart failure requiring hospitalization was diagnosed by clinical signs and symptoms, and chest radiographic findings. Stent thrombosis was defined as the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion. Angiographic follow-up was performed at 3 or 6 months or earlier if noninvasive evaluation or clinical presentation suggested ischemia. The occurrence of major clinical events was recorded and included death from any cause, reinfarction, target lesion revascularization (TLR), disabling stroke, or rehospitalization for congestive heart failure (CHF).
Statistical Analysis
Statistical analysis was performed with StatView 5.0 software (SAS Institute, Cary, NC, USA) except receiveroperating characteristic (ROC) curve analysis, which was performed with SPSS 11.0 (SPSS Inc, Chicago, IL, USA). Continuous variables are expressed as mean ± SD and categorical variables as frequency (%). Continuous variables were compared using Student's t-test. Categorical variables were compared with chi-square statistics. A ROC curve analysis was used to determine optimal cutoff point of cystatin C level to predict cardiovascular events during followup. It was calculated by determining the cystatin C level that provided the greatest sum of sensitivity and specificity. The Kaplan-Meier method was used for the estimation of event-free survival during follow-up and differences between the curves were compared using log-rank analysis. P value <0.05 was considered significant. Univariate analysis of factors affecting event-free survival was performed using factors in Tables 1 and 2 
Results
ROC curve analysis demonstrated cystatin C 0.955 as the cutoff level to predict cardiovascular events during followup (Figure 1 ). Patients were classified into 2 groups: (1) the higher cystatin C group (≥0.96 mg/L) (n=33) and (2) the lower cystatin C group (<0.96 mg/L) (n=38). Baseline clinical characteristics are presented in Table 1 . Serum creatinine concentration was higher in the higher cystatin C group than in the lower cystatin C group. There was no significant difference in Killip class, peak creatine kinase concentration or medication at discharge between the 2 groups. Table 2 shows angiographic and procedural characteristics. Thrombosis In Myocardial Infarction grade 2 or 3 flow was achieved in all patients and none received drugeluting stents. There was a trend toward more in-hospital deaths in patients with the higher cystatin C concentration Table 1 .
Circulation Journal Vol.73, September 2009
compared with the lower cystatin C group ( Table 3) . Before discharge (13.5±3.5 days after admission), left ventriculography was performed in 14 and 23 patients with the higher and lower cystatin C concentrations, respectively. Left ventricular ejection fraction was not different between the 2 groups (51.0±10.2% vs 52.9±9.6%, P=0.58).
Mean duration of clinical follow-up was 5.6±2.8 months. There was no significant difference in death, reinfarction, TLR, and disabling stroke between the 2 groups ( Table 3) . However, rehospitalization for CHF was higher in the higher cystatin C group than in the lower cystatin C group. Kaplan-Meier curves show lower event-free survival in patients with the higher cystatin C concentration than in those with the lower cystatin C concentration (Figure 2A) . On the other hand, there was no statistical difference in event-free survival between patients with and without serum creatinine elevation ( Figure 2B) . There was no statistical difference in event-free survival between patients with eGFR <60 ml/min and those with eGFR ≥60 ml/min ( Figure 2C) . Table 4 presents the results of multivariate analysis. Cystatin C was an independent predictor of cardiovascular events during follow-up.
Discussion
The present study showed more cardiovascular events in patients with the higher cystatin C concentration who underwent PCI for ST-elevation MI. On the other hand, there was no statistical difference in cardiovascular events between patients with and without an elevated serum creatinine concentration.
Cardiac diseases are responsible for almost 50% of allcause mortality in patients with end-stage renal disease. 14 It was recently reported that even mild renal dysfunction is associated with cardiovascular events. 1-8 Go et al. 4 evaluated the relationship between the eGFR and cardiovascular events in 1,120,295 adults. During follow-up (median 2.84 years), the adjusted hazard ratio for death was 1.2 with an eGFR of 45-59 ml · min -1 · 1.73 m -2 , 1.8 with an eGFR of 30-44 ml · min -1 · 1.73 m -2 , 3.2 with an eGFR of 15-29 ml · min -1 · 1.73 m -2 , and 5.9 with an eGFR of <15 ml · min -1 · 1.73 m -2 , and the adjusted hazard ratio for cardiovascular events increased inversely with the eGFR: 1.4, 2.0, 2.8, and 3.4, respectively. Recently Shiba et al 5 reported the prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Their Kaplan-Meier analysis revealed that the incidence of the combined events of all-cause death and admission for CHF was significantly higher in patients with reduced GFR.
The Framingham Heart Study showed that 8.9% of men and 8.0% of women had renal dysfunction defined as serum creatinine >1.5 mg/dl and >1.4 mg/dl, respectively. 8 Serum creatinine concentration or an estimation of creatinine clearance using the Cockcroft-Gault and MDRD equations has been the standard for estimating renal function. 7, 8 However, creatinine concentration is influenced by factors such as age, gender, muscle mass, physical activity, and diet. 9 so it is insensitive to small decreases in GFR or mild renal dysfunction. 10 Cystatin C has been introduced as a better endogenous marker of GFR. 11, 12 Jernberg et al 1 demonstrated cystatin C as a predictor of outcome in patients with non-ST-elevation acute coronary syndrome. The risk of death during follow-up increased with increasing levels of cystatin C. Patients in the 2 nd , 3 rd , and 4 th quartiles of cystatin C had a relative risk of subsequent death of 1.8, 3.2, and 11.7 compared with the lowest quartile. There was a significant association between cystatin C concentration and risk of subsequent MI. In their Cox regression model, cystatin C concentration was an independent predictor of mortality, although it was not for subsequent MI. In the present study, there was no difference in cardiac death during follow-up between patients with the lower and higher cystatin C concentration, which may be explained by the smaller number of patients and relatively short follow-up. Previous studies 2,3 showed a higher incidence of heart failure in patients with renal dysfunction. Sarnak et al 2 evaluated an incidence of heart failure in 4,384 persons without previous heart failure who had measurements of cystatin C and serum creatinine. During a median followup of 8.3 years, 763 (17%) participants developed heart failure. In Cox proportional hazards models, sequential quintiles of cystatin C concentration were associated with a stepwise increased risk for heart failure but quintiles of serum creatinine concentration were not. Early in the pathogenesis of heart failure, increased left atrial filling pressures trigger the release of atrial natriuretic peptide and inhibition of vasopressin, which leads to decreased renal sympathetic tone and diuresis. 15 Even mild renal dysfunction blunts these compensatory mechanisms 16 and may lead to sodium and water retention and extracellular fluid volume expansion, which can accelerate the progression of clinical heart failure. 15, 17 Renal dysfunction is also associated with diastolic dysfunction, left ventricular hypertrophy and vascular stiffness. 3 Furthermore, renal dysfunction may indicate a generalized atherosclerosis and vascular damage. 18 Cystatin C concentration may be useful to stratify high-risk patients with ST-elevation MI. Strategies to prevent heart failure, such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, may be more important in patients with an elevated cystatin C concentration. 19 
Study Limitations
In the present study, a higher incidence of rehospitalization for CHF occurred in patients with the higher cystatin C concentration than in those with the lower cystatin C concentration. However, there was no significant difference in death, reinfarction, disabling stroke, or TLR between the 2 groups. However, this was a retrospective study with a small number of patients and relatively short follow-up, which might be associated with the observed lack of a significant difference between groups. Further studies with a larger number of patients and longer follow-up are required to evaluate the usefulness of cystatin C concentration for predicting death, reinfarction, disabling stroke, or TLR during follow-up after MI.
Conclusion
Cystatin C may be associated with more cardiovascular events, mainly because of rehospitalization for CHF, after PCI in patients with ST-elevation MI.
